Halozyme Therapeutics Profit Margin

The latest profit margin for HALO is 26.93% as of September 2026. That compares with 47.91% in the prior-year period — down 43.8% year over year. That is above the Healthcare sector average of 19.13%. Investors often review this figure alongside Halozyme Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, HALO's profit margin moved from 47.91% to 26.93% — a 43.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Halozyme Therapeutics's valuation or profitability profile.

Against Healthcare companies, HALO currently prints 26.93% for profit margin, while the sector average sits near 19.13%. That is roughly 40.8% above the sector mean. Large gaps often invite a closer look at Halozyme Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Halozyme Therapeutics converts resources into returns. At 26.93%, HALO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 47.91% in the prior-year period — down 43.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HALO's profit margin (26.93%), review year-over-year change from 47.91%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.